BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Cancer Epigenetics Society - ECPv5.3.2.1//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Cancer Epigenetics Society
X-ORIGINAL-URL:https://ces.b2sg.org
X-WR-CALDESC:Events for Cancer Epigenetics Society
BEGIN:VTIMEZONE
TZID:Europe/Paris
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20180325T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20181028T010000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20181014
DTEND;VALUE=DATE:20181116
DTSTAMP:20260730T025119
CREATED:20181014T192526Z
LAST-MODIFIED:20181014T192526Z
UID:20746-1539475200-1542326399@ces.b2sg.org
SUMMARY:Institute Research Scientist
DESCRIPTION:ECLIPSE (Evolution of Cancer\, Leukemia and Immunity Project) is a novel organization within the MD Anderson Cancer Center\, Houston\, Texas\, with the mission of making MDACC and its partners recognized leaders in the identification and development of innovative immunooncology therapies that will cure all hematologic malignancies. \nThe primary requirement for an individual in this position is an experienced and highly motivated individual with hands-on experience in identification and validation of potential therapeutic targets for patients with advanced hematological malignancies. Such data generated from the team is expected to influence a broad array of decisions around target prioritization and generation of therapeutic modalities against those particular targets. The successful candidate will participate in cross-functional research to design and develop novel assays that will support an understanding of target biology. The selected candidate will be expected to work at the bench and contribute to development and implementation of potential biomarker strategies to support clinical development. Previous experience in biotech/pharma is highly preferred. \n\nKey Functions \n· Design and develop key experiments contributing to the conception\, execution\, and championing of novel targets\, technology platforms\, and strategies related to the development of biologics-based clinical candidate programs. \n· Provide expert technical guidance to others on project/task groups. Determine priorities and communicate to the team. Redirect operations as necessary to achieve objectives. \n· Collaborate with team members on a discovery platform using high throughput multi-omic technologies and apply scientific expertise in immunology and cancer biology to drive these programs in a multidisciplinary and exciting research team environment. \n· Interface with scientific staff both within the institution and outside\, including industry collaborators\, external consultants and stakeholders. \n· Commitment to keep abreast of current and emerging technological and scientific advancements in the field. \nEducation \nRequired: Bachelor’s degree in Biology\, Biochemistry\, molecular biology\, cell biology\, enzymology\, pharmacology\, chemistry or related field.\n\nPreferred: PhD in Biochemistry\, Molecular Biology or a related discipline.\n\nExperience\nRequired: Ten years of relevant research laboratory experience. With Master’s degree\, eight years of required experience and with PhD\, two years of required experience.\n\n· Experience with genetic (ie RNAi and CRISPR) and pharmacological (i.e. small molecule inhibitors or antibodies) approaches to study target biology utilizing state of the art molecular biology and biochemistry methods and assays.\n\n· Hands-on experience in standard in vitro and in vivo cell biology and immunology assays including\, but not limited to\, expansion of CTLs\, tetramer assays\, cytotoxicity assay\, functional assays like ADCC\, ADCP etc. is highly desirable. \n· Broad knowledge of cell culture techniques is required and knowledge of in vivo oncology models is desirable. \n· Extensive knowledge and experience in key areas of tumor biology such as oncogenic signaling\, tumor microenvironment\, tumor immunology\, metabolism\, epigenetic deregulation or anti-apoptosis as evidenced by publication in peer-reviewed journals. \n· Strong data analysis skills\, ability to interpret results and contribute to the design of follow-up experiments\, troubleshoot issues with assay performance. \n· Ability to effectively present results and conclusions to co-workers\, collaborators and senior leadership. \n· Ability to approach problems with curiosity and open mindedness; offer new ideas\, solutions and/or options. Notice current processes/products needing improvement and generate new options using own technical expertise and by utilizing multiple resources. \n· Ability to effectively challenge others in a group to identify creative approaches. \n· Ability to ensure scientific excellence\, quality and completeness of programs. \n· Strong knowledge of translational immunology such as identification of targets for immunotherapy in solid tumors and/or leukemia. \n· Excellent computer skills with working knowledge of commonly used research software programs.
URL:https://ces.b2sg.org/event/mdacc-14oct18/
LOCATION:MD Anderson Cancer Center\, 1515 Holcombe Blvd\, Houston\, TX\, 77030\, United States
CATEGORIES:Jobs
ATTACH;FMTTYPE=image/jpeg:https://ces.b2sg.org/wp-content/uploads/2017/05/MDAnderson.jpg
END:VEVENT
END:VCALENDAR